These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 37653822)

  • 1. FIB-4 is closer to FibroScan screen results to detecting advanced liver fibrosis and maybe facilitates NAFLD warning.
    Ding Y; Wang Z; Niu H; Deng Q; Wang Y; Xia S
    Medicine (Baltimore); 2023 Aug; 102(34):e34957. PubMed ID: 37653822
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FIB-4, APRI, and AST/ALT ratio compared to FibroScan for the assessment of hepatic fibrosis in patients with non-alcoholic fatty liver disease in Bandar Abbas, Iran.
    Amernia B; Moosavy SH; Banookh F; Zoghi G
    BMC Gastroenterol; 2021 Dec; 21(1):453. PubMed ID: 34861841
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fibroscan Compared to FIB-4, APRI, and AST/ALT Ratio for Assessment of Liver Fibrosis in Saudi Patients With Nonalcoholic Fatty Liver Disease.
    Fallatah HI; Akbar HO; Fallatah AM
    Hepat Mon; 2016 Jul; 16(7):e38346. PubMed ID: 27642348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AST/ALT ratio, APRI, and FIB-4 compared to FibroScan for the assessment of liver fibrosis in patients with chronic hepatitis B in Bandar Abbas, Hormozgan, Iran.
    Moosavy SH; Eftekhar E; Davoodian P; Nejatizadeh A; Shadman M; Zare S; Nazarnezhad MA
    BMC Gastroenterol; 2023 May; 23(1):145. PubMed ID: 37170243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.
    Eddowes PJ; Sasso M; Allison M; Tsochatzis E; Anstee QM; Sheridan D; Guha IN; Cobbold JF; Deeks JJ; Paradis V; Bedossa P; Newsome PN
    Gastroenterology; 2019 May; 156(6):1717-1730. PubMed ID: 30689971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study.
    Newsome PN; Sasso M; Deeks JJ; Paredes A; Boursier J; Chan WK; Yilmaz Y; Czernichow S; Zheng MH; Wong VW; Allison M; Tsochatzis E; Anstee QM; Sheridan DA; Eddowes PJ; Guha IN; Cobbold JF; Paradis V; Bedossa P; Miette V; Fournier-Poizat C; Sandrin L; Harrison SA
    Lancet Gastroenterol Hepatol; 2020 Apr; 5(4):362-373. PubMed ID: 32027858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic Accuracy of Noninvasive Markers of Steatosis, NASH, and Liver Fibrosis in HIV-Monoinfected Individuals at Risk of Nonalcoholic Fatty Liver Disease (NAFLD): Results From the ECHAM Study.
    Lemoine M; Assoumou L; De Wit S; Girard PM; Valantin MA; Katlama C; Necsoi C; Campa P; Huefner AD; Schulze Zur Wiesch J; Rougier H; Bastard JP; Stocker H; Mauss S; Serfaty L; Ratziu V; Menu Y; Schlue J; Behrens G; Bedossa P; Capeau J; Ingiliz P; Costagliola D;
    J Acquir Immune Defic Syndr; 2019 Apr; 80(4):e86-e94. PubMed ID: 30570529
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative Accuracy of Clinical Fibrosis Markers, Hepascore and Fibroscan® to Detect Advanced Fibrosis in Patients with Nonalcoholic Fatty Liver Disease.
    Bertot LC; Jeffrey GP; de Boer B; Wang Z; Huang Y; Garas G; MacQuillan G; Wallace M; Smith BW; Adams LA
    Dig Dis Sci; 2023 Jun; 68(6):2757-2767. PubMed ID: 36947289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased frequency of hepatic steatosis and fibrosis in patients with gout detected by transient elastography.
    Schlesinger N; Patel A; Rustgi VK; Yeo AE; Lipsky PE
    Clin Exp Rheumatol; 2024 Jan; 42(1):86-91. PubMed ID: 37497724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Noninvasive fibrosis tools in NAFLD: validation of APRI, BARD, FIB-4, NAFLD fibrosis score, and Hepamet fibrosis score in a Portuguese population.
    Rigor J; Diegues A; Presa J; Barata P; Martins-Mendes D
    Postgrad Med; 2022 May; 134(4):435-440. PubMed ID: 35332833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum cytokeratin-18 and its relation to liver fibrosis and steatosis diagnosed by FibroScan and controlled attenuation parameter in nonalcoholic fatty liver disease and hepatitis C virus patients.
    Darweesh SK; AbdElAziz RA; Abd-ElFatah DS; AbdElazim NA; Fathi SA; Attia D; AbdAllah M
    Eur J Gastroenterol Hepatol; 2019 May; 31(5):633-641. PubMed ID: 30839434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Accuracy of FibroScan in analysis of liver fibrosis in patients with concomitant chronic Hepatitis B and nonalcoholic fatty liver disease.
    Li Q; Huang C; Xu W; Hu Q; Chen L
    Medicine (Baltimore); 2020 Jun; 99(23):e20616. PubMed ID: 32502037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Study on the diagnostic value of transient elastography, APRI and FIB-4 for liver fibrosis in children with non-alcoholic fatty liver disease].
    He SL; Li SJ; Liu M; Ouyang WX; Chen WJ; Zheng X; Jiang T; Tan YF; Kang Z; Qin XM; Yu Y
    Zhonghua Gan Zang Bing Za Zhi; 2022 Jan; 30(1):81-86. PubMed ID: 35152674
    [No Abstract]   [Full Text] [Related]  

  • 14. Accuracy of transient elastography-FibroScan®, acoustic radiation force impulse (ARFI) imaging, the enhanced liver fibrosis (ELF) test, APRI, and the FIB-4 index compared with liver biopsy in patients with chronic hepatitis C.
    Ragazzo TG; Paranagua-Vezozzo D; Lima FR; de Campos Mazo DF; Pessoa MG; Oliveira CP; Alves VAF; Carrilho FJ
    Clinics (Sao Paulo); 2017 Oct; 72(9):516-525. PubMed ID: 29069254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FibroScan-aspartate transaminase: A superior non-invasive model for diagnosing high-risk metabolic dysfunction-associated steatohepatitis.
    Yin JY; Yang TY; Yang BQ; Hou CX; Li JN; Li Y; Wang Q
    World J Gastroenterol; 2024 May; 30(18):2440-2453. PubMed ID: 38764767
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liver Stiffness and Steatosis Measurements with iLivTouch and FibroScan: A Comparative Study.
    Özercan M; Melekoğlu Ellik Z; Parmaksız A; Gümüşsoy M; Duman S; Örmeci N
    Turk J Gastroenterol; 2024 Jun; 35(8):634-642. PubMed ID: 39150398
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Correlation of liver stiffness measured by FibroTouch and FibroScan with Ishak fibrosis score in patients with chronic hepatitis B].
    Chen GF; Ping J; Gu HT; Zhao ZM; Zhou Y; Xing F; Tao YY; Mu YP; Liu P; Liu CH
    Zhonghua Gan Zang Bing Za Zhi; 2017 Feb; 25(2):145-150. PubMed ID: 28297803
    [No Abstract]   [Full Text] [Related]  

  • 18. Correlation between Fibroscan and laboratory tests in non-alcoholic fatty liver disease/non-alcoholic steatohepatitis patients for assessing liver fibrosis.
    Al Danaf L; Hussein Kamareddine M; Fayad E; Hussain A; Farhat S
    World J Hepatol; 2022 Apr; 14(4):744-753. PubMed ID: 35646268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Accuracy of liver stiffness measurement and controlled attenuation parameter using FibroScan
    Oeda S; Takahashi H; Imajo K; Seko Y; Ogawa Y; Moriguchi M; Yoneda M; Anzai K; Aishima S; Kage M; Itoh Y; Nakajima A; Eguchi Y
    J Gastroenterol; 2020 Apr; 55(4):428-440. PubMed ID: 31654131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Validation of the accuracy of the FAST™ score for detecting patients with at-risk nonalcoholic steatohepatitis (NASH) in a North American cohort and comparison to other non-invasive algorithms.
    Woreta TA; Van Natta ML; Lazo M; Krishnan A; Neuschwander-Tetri BA; Loomba R; Mae Diehl A; Abdelmalek MF; Chalasani N; Gawrieh S; Dasarathy S; Vuppalanchi R; Siddiqui MS; Kowdley KV; McCullough A; Terrault NA; Behling C; Kleiner DE; Fishbein M; Hertel P; Wilson LA; Mitchell EP; Miriel LA; Clark JM; Tonascia J; Sanyal AJ;
    PLoS One; 2022; 17(4):e0266859. PubMed ID: 35427375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.